2,3-二氯-4-羟基苯甲醛 | 16861-22-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2,3-二氯-4-羟基苯甲醛
• 英文名称: 2,3-dichloro-4-hydroxybenzaldehyde
• 英文别名: dichloro-2,3 hydroxy-4 benzaldehyde；4-hydroxy-2,3-dichlorobenzaldehyde；2,3-dichloro-4-hydroxy-benzaldehyde；2,3-dichloro-4hydroxybenzaldehyde；2,3-Dichlor-4-hydroxybenzaldehyd
• CAS: 16861-22-6
• 化学式: C₇H₄Cl₂O₂
• 分子量: 191.014
• InChiKey: GEORDJYJYUGGSO-UHFFFAOYSA-N

物化性质

• 熔点：
  184-185 °C
• 沸点：
  278.6±35.0 °C(Predicted)
• 密度：
  1.547±0.06 g/cm3(Predicted)
• 保留指数：
  1455;1463;1467;1463;1463;1474;1479;1463

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2913000090

反应信息

• 作为反应物：
  描述：

  2,3-二氯-4-羟基苯甲醛 在 四(三苯基膦)钯 吡啶 、 三溴化硼 、 sodium carbonate 作用下， 以 乙二醇二甲醚 、 二氯甲烷 、 水 为溶剂， 反应 3.5h， 生成 2',3'-dichloro-4'-(dibromomethyl)-3-fluorobiphenyl-4-ol
  参考文献：
  名称：

  ERβ Ligands. Part 2: Synthesis and structure–activity relationships of a series of 4-hydroxy-biphenyl-carbaldehyde oxime derivatives

  摘要：

  A series of biphenyl carbaldehyde oximes (6) was prepared and shown to have significant selectivity for the estrogen receptor-beta (ERbeta). The exploitation of the oxime moiety as a hydrogen bond donating group, which mimicked the C-ring of genistein makes these compounds unique. Molecular modeling studies showed the oxime moiety hydrogen bonding to the histidine residue, which was supported by the structure-activity relationships. The most potent compounds in this study had IC50 values in a radio-liaand binding assay of between 8-35 nM. Among the most selective compounds were 6i and 6s (49- and 31-fold ERbeta selective, respectively). (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.03.028
• 作为产物：
  描述：

  2,3-二氯茴香醚 在 三溴化硼 、 四氯化钛 作用下， 以 二氯甲烷 为溶剂， 反应 5.0h， 生成 2,3-二氯-4-羟基苯甲醛
  参考文献：
  名称：

  ERβ Ligands. Part 2: Synthesis and structure–activity relationships of a series of 4-hydroxy-biphenyl-carbaldehyde oxime derivatives

  摘要：

  A series of biphenyl carbaldehyde oximes (6) was prepared and shown to have significant selectivity for the estrogen receptor-beta (ERbeta). The exploitation of the oxime moiety as a hydrogen bond donating group, which mimicked the C-ring of genistein makes these compounds unique. Molecular modeling studies showed the oxime moiety hydrogen bonding to the histidine residue, which was supported by the structure-activity relationships. The most potent compounds in this study had IC50 values in a radio-liaand binding assay of between 8-35 nM. Among the most selective compounds were 6i and 6s (49- and 31-fold ERbeta selective, respectively). (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.03.028

文献信息

• Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
  申请人：Abbott Laboratories

  公开号：US20040116518A1

  公开（公告）日：2004-06-17

  The present invention relates to novel cinnamide compounds that are useful for treating inflammatory and immune diseases and cerebral vasospasm, to pharmaceutical compositions containing these compounds, and to methods of inhibiting inflammation or suppressing immune response in a mammal.

  本发明涉及新型肉桂酰胺化合物，用于治疗炎症和免疫性疾病以及脑血管痉挛，以及含有这些化合物的药物组合物，以及在哺乳动物中抑制炎症或抑制免疫反应的方法。
• DERIVATIVES OF SUBSTITUTED 3-PHENYL-1-(PHENYLTHIENYL)PROPAN-1-ONES AND OF 3-PHENYL-1-(PHENYLFURANYL) PROPAN-1-ONES, PREPARATION AND USE
  申请人：Delhomel Jean-Francois

  公开号：US20100029745A1

  公开（公告）日：2010-02-04

  The present invention relates to compounds derived from substituted 3-phenyl-1-(thien-2-yl)propan-1-ones, pharmaceutical compositions comprising them as well as their therapeutic applications, notably in the field of human and animal health.

  这项发明涉及从取代的3-苯基-1-(噻吩-2-基)丙酮衍生的化合物，包括它们的药物组合物以及它们在人类和动物健康领域的治疗应用，特别是治疗应用。
• Aryloxyalkanoic Acids as Non-Covalent Modifiers of the Allosteric Properties of Hemoglobin
  作者：Abdelsattar Omar、Mona Mahran、Mohini Ghatge、Faida Bamane、Mostafa Ahmed、Moustafa El-Araby、Osheiza Abdulmalik、Martin Safo

  DOI：10.3390/molecules21081057

  日期：——

  evaluated 18 new compounds (KAUS II series) for enhanced antisickling activities. Surprisingly, select test compounds showed no antisickling effects or promoted erythrocyte sickling. Additionally, the compounds showed no significant effect on Hb oxygen affinity (or in some cases, even decreased the affinity for oxygen). The X-ray structure of deoxygenated Hb in complex with a prototype compound, KAUS-23,

  立体特异性抑制镰状血红蛋白聚合物形成和/或变构增加 Hb 对氧的亲和力的血红蛋白 (Hb) 修饰剂已被证明可以预防镰状细胞病 (SCD) 的主要病理生理，特别是 Hb 聚合和红细胞镰状化。目前正在临床研究几种此类化合物用于治疗 SCD。基于先前报道的具有抗镰刀化特性的取代芳氧基链烷酸的非共价 Hb 结合特性，我们设计、合成和评估了 18 种新化合物（KAUS II 系列），以增强抗镰刀化活性。令人惊讶的是，选择的测试化合物没有表现出抗镰刀化作用或促进红细胞镰化。此外，这些化合物对 Hb 氧亲和力没有显着影响（或在某些情况下，甚至降低了对氧的亲和力）。与原型化合物 KAUS-23 复合的脱氧 Hb 的 X 射线结构显示，效应物结合在蛋白质的中央水腔中，为观察到的功能和生物活性提供了原子水平的解释。虽然结构修饰没有导致预期的生物学效应，但这些发现为设计候选抗镰刀菌剂提供了重要方向，并为新型 Hb
• Sulfonamide derivatives for the treatment of diseases
  申请人：Brown Daniel Alan

  公开号：US20050182091A1

  公开（公告）日：2005-08-18

  The invention relates to compounds of formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.

  该发明涉及公式（1）的化合物，以及用于制备、用于制备的中间体、含有和使用这些衍生物的组合物的过程。根据本发明的化合物在许多疾病、紊乱和状况中具有用途，特别是在炎症性、过敏性和呼吸系统疾病、紊乱和状况中。
• [(5,6,9a-substituted-3-oxo-1,2,9,9a-tet
  申请人：Merck & Co., Inc.

  公开号：US04356313A1

  公开（公告）日：1982-10-26

  The invention relates to novel [(5,6,9a-substituted-3-oxo-1,2,9,9a-tetrahydro-3H-fluoren-7-yl)oxy]alkanoi c and cycloalkanoic acids and their analogs, esters, salts and derivatives. These compounds are synthesized by methods selected from a number of synthetic routes depending on the particular structure, choice of intermediate or preferred reaction sequence. The compounds are useful in the treatment and prevention of injury to the brain and spinal chord due to accidents, ischemic stroke and hydrocephalus; compositions for such uses are also disclosed.

  该发明涉及新型[(5,6,9a-取代-3-氧代-1,2,9,9a-四氢-3H-芴-7-基)氧基]烷酸和环烷酸以及它们的类似物、酯、盐和衍生物。这些化合物通过从多种合成途径中选择的方法合成，具体取决于特定结构、中间体选择或首选反应顺序。这些化合物在治疗和预防由事故、缺血性中风和脑积水导致的大脑和脊髓损伤方面具有用途；还公开了用于这些用途的组合物。